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ecommendations for Successful Training
n Methods of Delivery of Biologics for
ardiac Regeneration
Report of the International Society for Cardiovascular Translational Research
abil Dib, MD, MSC, Philippe Menasche, MD, PHD, Jozef J. Bartunek, MD, PHD,
ndreas M. Zeiher, MD, Andre Terzic, MD, PHD, Nicolas A. Chronos, MD,
imothy D. Henry, MD, Nicholas S. Peters, MD, PHD, Francisco Ferna´ndez-Avilés, MD, PHD,
agdi Yacoub, MD, PHD, Timothy A. Sanborn, MD, Anthony DeMaria, MD,
ichard A. Schatz, MD, Doris A. Taylor, PHD, Shmuel Fuchs, MD, Silviu Itescu, MD,
eslie W. Miller, MD, Jonathan H. Dinsmore, PHD, George D. Dangas, MD, PHD,
effrey J. Popma, MD, Jennifer L. Hall, PHD, David R. Holmes, JR, MD
he ﬁeld of myocardial regeneration (angiogenesis and myogenesis) might prove to play an important
ole in the future management of cardiovascular disease. Stem cells are currently undergoing testing in
hase I and Phase II clinical trials. Methods of delivery will affect the outcome of such therapies, per-
aps signiﬁcantly. This document provides suggested guidance in 4 methods of delivery: endocardial,
ntracoronary, coronary sinus, and epicardial. (J Am Coll Cardiol Intv 2010;3:265–75) © 2010 by the
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ihe mission of the International Society for Car-
iovascular Translational Research (ISCTR) is to
xpedite scientific discovery into clinical applica-
ion by providing an environment for collaboration
nd guidance among basic scientists, clinical scien-
ists, sponsors, and regulatory authorities and to
isseminate the science among the scientific com-
unity; promote research, development, and ap-
lication of standards of care and guidelines; influ-
nce health care policy; educate the public; and
mprove the wellbeing of patients.
The report of the American Heart Association
or the year 2005 documented that the incidence of
yocardial infarction (MI) in the U.S. reached
50,000. Only one-third of these patients had a
ull recovery. Approximately 550,000 developed
ongestive heart failure, and 150,000 patients were
iagnosed with refractory angina despite optimal
edical care. The cost of coronary artery disease
lease see the end of this paper for full author disclosures.s
anuscript received August 18, 2009; revised manuscript received
ecember 21, 2009, accepted December 22, 2009.nd congestive heart failure reached 170 billion
ollars for that year (1).
The field of myocardial regeneration (angiogen-
sis and myogenesis) might prove to play an
mportant role in the future management of such
atients. Gene, protein, and stem cell therapies are
urrently being tested in both Phase I and Phase II
linical trials in the U.S. as well as Europe and
sia. Methods of delivery will likely affect the
utcome of such therapies, perhaps significantly.
his document aims to provide adequate guidance
or delivery methods that fall into 4 categories:
) endocardial; 2) intracoronary; 3) coronary sinus;
nd 3) epicardial.
rogram Summary
he purpose of the task force recommendations is
o provide suggested guidance for training of phy-
icians on the delivery of stem cells for myocardial
egeneration. The catheter training program will
rovide training to personnel, including physician
nvestigators, cardiac catheterization laboratory
taff, and coordinators involved in clinical trials
u
t
s
r
m
p
v
p
D
T
a
t
r
U
S
b
r
a
t
I
s
a
t
i
s
u
A
w
f
v
o
s
T
i
p
m
E
T
i
e
P
h
e
3
a
I
a
d
s
t
a
a
i
p
c
p
a
c
l
r
C
f
i
g
C
(
s
t
t
a
i
F
n
l
a
t
i
A
a
I
I
I
S
T
L
d
L
L
v
M
O
P
c
R
2
3
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0
M A R C H 2 0 1 0 : 2 6 5 – 7 5
Dib et al.
Delivery Methods for Cardiac Regeneration
266sing the devices. However, this document will emphasize
he satisfactory training of physician investigators.
The complete training program for the catheter delivery
ystem consists of 3 phases. Phase 1 should include a tutorial
elated to the variety of available percutaneous catheters and
apping technology. Phase 2 consists of instruction in
re-clinical (porcine) endocardial injections. Phase 3 in-
olves investigational clinical cases proctored by the lead
hysician trainer.
elivery of Biologics
he delivery methods identified use catheter systems to
ccurately deliver stem cells or other therapeutic substances
o the myocardium. Biologics can be delivered via different
outes: intracoronary (IC), intramyocardial (IM), and IV.
There are advantages and dis-
advantages of each route and
variable retention rate of cells in
the myocardium. Hou et al. (2)
demonstrated retention rates of
3% (IC), 11% (IM), and 3%
(IV). High numbers of cells con-
tinue to travel to the lungs—
47% (IC), 26% (IM), 43%
(IV)—and lesser numbers travel
to the liver, spleen, and kidneys.
A limitation of cell therapy for
heart disease is that stem cells
injected directly into the myocar-
dium are capable of entering the
vasculature and migrating to re-
mote organs. A variety of factors
might play a role in the retention
of stem cells in the myocardium,
including adding collagen matrix
to the cells (3–6).
nresolved Issues
everal issues remain to be addressed. There is a need for a
etter understanding of the mechanisms underlying cell
etention after coronary delivery in relation to the timing
nd extent of myocardial injury. This might better define
he effective time window for coronary cell transfer after MI.
n this regard, effects of ischemic pre-conditioning or
imilar approaches, such as ultrasound, should be explored
s new approaches to enhance acute cell retention. Although
he ideal end point for cell therapy is unknown at this point
n time, many investigators have used objective findings
uch as size of infarct in patients with acute MI. Others have
sed quality-of-life assessments such as New York Heart
ssociation functional classifications or Minnesota Living
bbreviations
nd Acronyms
C  intracoronary
M  intramyocardial
SCTR  International
ociety for Cardiovascular
ranslational Research
AD  left anterior
escending
AO  left anterior oblique
V  left
entricle/ventricular
I  myocardial infarction
TW  over-the-wire
VC  premature ventricular
ontraction
AO  right anterior oblique
D  2-dimensional
D  3-dimensionalith Heart Failure questionnaires. Objective measurements eor patients with congestive heart failure, such as left
entricular (LV) dimension, can be measured by echocardi-
graphy, and LV volume can be measured by nuclear
ingle-photon emission computed tomography imaging.
he exercise stress test and nuclear imaging have been used
n patients with refractory angina. Overall, composite end
oints such as repeat hospital stay, revascularization, or
ortality might be desirable.
ndocardial Delivery of Biologics
his delivery method uses catheter systems to accurately
nject stem cells or other therapeutic substances into the
ndocardium of the LV.
ersonnel. The training physician/proctor will provide all
ands-on training. The trainer will be responsible for the
valuation of all investigator trainees, proctoring the initial
clinical cases; documentation of the training; and needs for
dditional training. The trainer should be board certified in
nterventional Cardiology or equivalent if outside the U.S.
nd established as an expert in the field of catheter-based
elivery and cell or gene therapy The trainer will have
ignificant experience and demonstrate successful comple-
ion of 20 cell or gene transplant procedures in large animals
nd 20 cell or gene transplant procedures in humans. In
ddition, the trainer should be a knowledgeable and capable
nstructor or proctor.
The preclinical staff, including the veterinarian, will have
rior extensive training and experience in the oversight,
are, and welfare of the animals. The clinical specialists are
ersonnel who have extensive experience training customers
nd in providing technical support and education. The
linical trial research coordinator and cardiac catheterization
aboratory staff will assist with the procedure and with case
eport documentation during clinical cases.
atheter systems. There are varieties of catheters available
or endoventricular delivery. For endoventricular delivery,
nvestigators use either a fluoroscopic 2-dimensional (2D)
uidance system (Biocardia helical infusion catheter; Bio-
ardia, South San Francisco, California) or a 3-dimensional
3D) guidance system (Myostar Injection Catheter, Bio-
ense Webster, Diamond Bar, California) (7,8). The advan-
ages of 3D over 2D guidance are that the 3D system has
he ability to identify the area intended for injection as well
s the boundaries of the MI. Consequently, the investigator
s able to perform the injections with increased accuracy.
urthermore, 3D guidance potentially allows for homoge-
eous distribution of the injections, decreasing the risk of
ocal toxicity (adverse event related to cell concentration)
nd increasing efficacy. The disadvantage of 3D guidance is
hat the current mapping system requires significant train-
ng and skills and can be time consuming.
BioCardia’s Helical Infusion Catheter (Fig. 1) is a cath-
ter with a small, hollow, distal corkscrew needle, which
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267ight be rotated into tissue to provide active fixation during
rug delivery similar to the active fixation electrodes used in
ardiac pacing. This catheter is under investigational use in
ultiple ongoing clinical trials (9).
This system provides a means for fixation to the beating
eart wall, uses simplified fluoroscopic imaging, crosses the
ortic arch and valve safely over a guidewire with BioCar-
ia’s unique steerable guide, and allows 3 degrees of freedom
o maximize operator control.
The Morph Deflectable Guide Catheter can be used to
teer a guidewire across the aortic valve for transendocardial
elivery from within the LV. For transendocardial delivery,
he Morph Deflectable Guide Catheter is advanced over the
Figure 1. BioCardia Helical Infusion Catheter With Dual Fluid Ports
The BioCardia Helical Infusion Catheter has 2 ﬂuid ports, 1 for therapeutic
agent and 1 for contrast. Image reprinted with permission of Springer Sci-
ence and Business Media (17).
Figure 2. Myostar Cordis-Biosense Webster Needle Injection CatheterImages have been reprinted with permission of Springer Science and Business Mediaire, and the wire is removed to allow for advancement and
avigation of the Helical Infusion Catheter (10).
The Myostar Injection Catheter (Biosense Webster) is a
ulti-electrode, percutaneous catheter with a deflectable tip
nd injection needle designed to inject soluble agents or cells
ransendocardially into the myocardium (Fig. 2). The tip of
he injection catheter is equipped with a location sensor and
retractable, hollow, 27-gauge nitinol needle for fluid
nd/or cell delivery. Tip deflection is controlled at the
roximal end by a tubular hand piece holding a piston and
ull-wire mechanism. The high-torque shaft allows for
ontrolled rotation of the curved tip to facilitate accurate
ositioning toward the desired site for agent injection
11,12). A second handle located at the proximal end of the
atheter allows for controlled needle extension from the
istal tip. The extended length of the needle is adjustable
rom 2 to 10 mm. The handle has a standard luer lock fitting
or a syringe connection. The catheter interfaces with the
OGA (Biosense Webster) 3D electromagnetic cardiac
apping system for navigated local agent delivery into the
yocardium (13). The NOGA map is a 3D reconstruction
f the LV from points obtained by the mapping catheter.
he NOGA map discriminates between areas of MI, the
order zone, and normal myocardium (Fig. 3). With the
ombination of echocardiography and low voltage, one can
dentify the area of MI and thin wall (14).(17).
T
d
t
A
d
a
c
r
p
m
l
a
P
p
o
a
c
m
a
p
T
t
c
c
i
h
A
i
i
p
i
i
b
L
m
s
d
m
s
i
d
d
t
i
s
a
t
A
p
t
i
a
m
p
C
s
m
t
t
i
i
m
s
p
s
S
a
n
m
t
c
1
2
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 3 , 2 0 1 0
M A R C H 2 0 1 0 : 2 6 5 – 7 5
Dib et al.
Delivery Methods for Cardiac Regeneration
268utorial and injection catheter preparation instructions. A
escriptive overview of the catheter system and instructive
raining can be provided by the manufacturer representative.
didactic review of all devices will include manufacturer
irections for use, capacities, contraindications, and associ-
ted risks. Instruction should include: hands-on practice of
atheter manipulation and injection procedure; review of the
isks of the procedure and criteria for technical success;
ractice of injection catheter loading and delivery require-
ents; and a primer on how to determine catheter needle
ength and documentation of needle measurements before
nd after injection.
re-clinical training. The objective of the preclinical training
rogram is to instruct and evaluate procedural performance
f clinical investigators in the use of the catheter system in
porcine model as preparation for use in humans. The
linical indication for cell therapy might involve the treat-
ent of acute MI, chronic MI, heart failure, and stable
ngina. Each clinical scenario will require different skills,
roficiency, and training, but basic requirements are similar.
he requisite instruction should be focused on targeting the
herapy to the area of MI or ischemia while minimizing
omplications such as vascular injury and perforation. Myo-
ardial tissue textures differ among normal musculature,
schemic tissue, peri-infarct zones, acute or chronic MI, and
Figure 3. NOGA Mapping in Porcine Model
NOGA mapping in porcine model shows the location of injections in nor-
mal myocardium (blue and green), chronic infarction (red), and border
zone of infarction (yellow). Images have been reprinted with permission of
Springer Science and Business Media (17).eart failure.nimal model. For catheter-based cell transplantation stud-
es, a large animal model is required to simulate conditions
n humans (15). A swine model of MI produced by coil
lacement or balloon inflation in the left anterior descend-
ng (LAD) artery is a reproducible model and simulates MI
n a human heart. de Prado et al. (16) demonstrated LAD
alloon occlusion for 75 min caused a 20% compromise of
V and a mortality rate of 33%.
A coil model is preferred to surgical ligation, because
ortality rates have been much lower with coils versus
urgery (9% vs. 50%) (18). By placing coils distal to the
iagonal, one can produce ejection fractions of 44% at 1
onth and 41% at 3 months after MI (11). The post-MI
wine remodeling process is similar to humans. The clinical
nvestigator will be required to make an adjustment in the
elivery technique by increasing pressure on the catheter
uring needle advancement, due to an increase in fibrotic
issue in the area of chronic MI, and must be aware that the
ncidence of premature ventricular contractions (PVCs)
econdary to needle advancement is less likely. The Food
nd Drug Administration has accepted the described model
o evaluate safety and efficacy of stem cell therapies.
cute MI model. Myocardial infarction can be induced
ercutaneously in pigs by either balloon or coil occlusion in
he coronary arteries. The MI can be achieved via balloon
nflation within 60 to 90 min, whereas the coil method
chieved total occlusion of blood flow in approximately 10
in. In approximately 4 to 10 days after MI injection,
rocedures can be done.
hronic MI model. In the swine model, coil infarction forms
car tissue after 6 weeks (18). This resembles the chronic
yocardial injury that occurs in humans. The procedure and
raining on the swine 6 weeks after MI will serve to qualify
he trainee for cell transplantation in chronic MI and
schemic cardiomyopathy in humans.
In the chronic MI swine model, where contrast was
njected in the myocardium under 3D electromechanical
apping guidance, only 30% of the injections within the
car were associated with PVCs. The standard notion that
roducing a PVC during needle penetration is indicative of
uccessful injection might not apply for infarcted tissue.
ixty percent of the injections in the border zone were
ssociated with PVCs. However, 90% of the injections in
ormal myocardium were associated with PVCs (17). This
odel will require more technical skills and training than
he other models to guarantee successful injections. The
hallenges emerge from the following:
. Lack of PVCs that provide assurance of needle penetra-
tion of the myocardium.
. The scar tissue might make needle penetration more
difficult.
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269. The reduced thickness of the scarred myocardium might
increase the risk of perforation and extravasations into
pericardial space.
Consequently, operators need to develop tactile familiar-
ty with the catheter and stability of the catheter during
njections.
rocedure detail. LEFT HEART CATHETERIZATION. An 8-F
heath is introduced into the femoral artery after puncturing
he femoral artery with the modified Seldinger technique or
ia a surgical cut down. After insertion of the arterial sheath,
eparin is administered and supplemented as needed to
aintain an activated clotting time of 200 to 250 s through-
ut the interventional portion of the procedure. A 6-F
igtail catheter will be used for left ventriculography per-
ormed in left anterior oblique (LAO) 7° to 15° and right
nterior oblique 90 views (porcine model).
The right anterior oblique projection will identify the
nterior basal, mid anterior, apical anterior, inferior, mid
nferior, and inferior basal segments. The LAO projection
ill identify the basal lateral, mid lateral, apical lateral,
pical septal, mid septal, and basal septal segments (Fig. 4).
NTRA-MYOCARDIAL INJECTION PROCEDURE. The catheter
s placed via the femoral sheath and advanced to the aortic
alve in a retrograde fashion. After full tip deflection in the
escending aorta, gently prolapse the rounded distal tip
cross the aortic valve, then straighten the catheter tip
oward the apex within the LV cavity.
The injection catheter is oriented to the treatment zone
ith fluoroscopic guidance. If the 3D guidance system is
sed, 3D imaging and mapping are also used. The injection
eedle is extended into the myocardium to a depth of
pproximately 4 to 6 mm, adjusted to wall thickness on the
asis of prior echocardiographic assessment (approximately
0% of wall thickness). Four injections/LV wall (anterior,
ateral, inferior, septal) are performed for a total of 16
njections. The operator must accurately make 3 of the 4
Figure 4. Segments of the RAO and LAO Projections
Ant  anterior; Inf  inferior; LAO  left anterior oblique; RAO  right anterionjections/wall. Each injection contains 0.2 ml of solution lnd is to be infused over a minimum of 20 s. A different
olor dye for each wall is used containing diluted mixed
ontrast tissue marking dye (10% dye  40% contrast, 50%
aline). The time (seconds) and volume (milliliters) for each
njection are to be documented.
Accurate delivery will be evaluated by targeting well-
efined areas on the NOGA map, provided 3D mapping
ystem is used. In this case, injections should be separated by
pproximately 1 cm (Fig. 3). If a 2D catheter system is used,
njection sites will be evaluated by a pathology exam. In
ither case, leakage of dye into the systemic circulation will
e considered a failure of the procedure.
ATHOLOGY EVALUATION. The goal of the gross heart
issue evaluation is to accurately identify injection sites and
valuate any structural injuries. Because a different colored
ye was used for each wall, the trainer should easily be able
o identify the sites (Fig. 5).
The animal will be killed with pentobarbital per institu-
ional standard operating procedure. The heart will be
xplanted, and gross dissection of the LV will be performed.
he criteria for a successful procedure are as follows: the
bsence of LV perforation, pericardial effusion, and damage
o cardiac structure (e.g., aortic and mitral valve structures,
oronary and great vessels) due to the test device. Achieve
n injection accuracy of 75% (3 of 4 injections/wall with the
ssigned dye).
raining goals. The trainer should visually assess trainee’s
echnique, handling of equipment, and catheter use in
onjunction with fluoroscopy. The following training
oals should be verified by the physician trainer: the
roper targeting of sites; animal stability including ab-
ence of sustained arrhythmias, ventricular tachycardia
ith/without cardioversion, severe hypotension (systolic
lood pressure 60 mm Hg), and sustained tachycardia
r bradycardia (change in heart rate 40% from base-
que.ine); and the ability to manipulate the catheter to achieve
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270sufficiently stable endocardial position to perform the
njection procedure.
Training should include techniques to avoid complica-
ions such as vascular injury of the iliac artery and aorta
uring the advancement of the catheter to the LV; catheter
rauma to the coronaries due to inadvertent placement of
he injection catheter into the coronary ostium, which might
esult in dissection, abrupt closure, perforation, or severe
schemia; trauma to the aortic valve causing hemodynamic
ompromise associated with acute aortic regurgitation; per-
oration or trauma to the mitral valve structure due to
lacement of the catheter or injector or due to needle
uncture and injections; and LV perforation due to catheter
lacement or needle penetration into the pericardial space.
If the criteria described in the preceding text are met, the
rainee should have successfully completed the preclinical
raining. If the goals are not met, the trainee should be
equired to repeat the training program. The investigator/
rainee should also repeat the entire training protocol if
here are any procedural adverse events during the clinical
rial directly related to the injection (or mapping if the
lectromechanical mapping system is being used) or if more
han 3 months of time have lapsed between completion of
he training program and the first clinical case. Therefore it
s recommended that the catheter training program not be
ompleted until investigator site institutional review board
pproval and initial patient screening and consent have been
ompleted.
linical training/case proctoring. After successful comple-
ion of the tutorial and preclinical training (i.e., all skills
Figure 5. Methylene Blue Dye as Injected With the MyoStar
Injection Catheter
Arrows indicate site of injection. Images have been reprinted with permis-
sion of Springer Science and Business Media (17).riteria have been met), the investigator trainee might begin fcheduling clinical cases. The first 3 cases should include a
epresentative of the catheter manufacturer and a physician
rainer. Due to the possibility of reduced proficiency in this
ethod over time, it is critical that there is no more than a
-month lapse between completion of preclinical training
nd the first patient procedure and every following
rocedure.
After each mentored procedure, the investigator trainee’s
kills and knowledge of the catheter system will be docu-
ented and reviewed by a trainer physician proctor. The
hysician proctor might make further training recommen-
ations if necessary. Any procedural event that occurs
uring the injection will be documented. The physician
roctor has the option to increase the number of required
entored cases and can recommend remediation of any part
f training.
raining program modiﬁcation. This training program
hould be reviewed at least annually by the physician trainer
nd might be modified on the basis of trainee feedback,
ncluding content and passing requirements (i.e., preclinical
valuation, number of proctored cases) or any Food and
rug Administration recommendations or feedback. Mod-
fication to training might also be based on the progress of
linical trials and Data Safety Monitoring Board recom-
endations, new information on the device/interactions,
he evaluation of procedure effectiveness, investigator qual-
fications, emerging issues and trends, any clinical safety
esults pertaining to use of the device, protocol-specific
equirements, or updated source documents upon which
raining is based.
Suggested basic requirements should include:
. Board certified in interventional cardiology or equivalent
if outside of the U.S.
. Attendance at 2 days of animal training.
. Demonstrate acceptable mapping skills; identification of
the apex, mitral valve, left bundle branch location, and
LV outflow tract.
. Perform a total of 16 contrast injections in the appro-
priate animal model, 4 in each wall (anterior, inferior,
lateral, and septal).
. Able to target 75% (12 of 16 injections) of total required
injections and 75% (3 of 4 injections) in each wall
identified by gross pathology (Fig. 5) for 2D catheter use
and by NOGA mapping for 3D catheter use.
. Absence of the following serious complications during
the procedure: death, perforation, contrast leak into
systemic circulation, left bundle branch block, mitral
valve damage, aortic dissection, and coronary artery
dissection.
. Perform the 3 initial proctored clinical cases successfully.
raining records. All training sessions should be recorded
nd copied on appropriate (dated and signed) case report
orms and filed with the sponsor and individual investiga-
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271ional sites. The ISCTR will issue certificates and retain
opies of completed training records.
C Delivery of Biologics
oronary cell transfer is based on the combination of
ultiple factors that influence myocardial cell retention
fter myocardial injury. These factors include cell adhesion
n the endothelial layer, transendothelial (vascular) passage
nd migration, and the presence of chemoattractive and
dhesive forces in the myocardium. These factors lead
ltimately to cell retention in the perivascular region and in
he myocardium (19). If cells are given IC—mainly bone
arrow mono nuclear cells—they might reside in any zone
r location. Most of the current clinical trials are using a
ose escalating model to determine the optimal number of
ells delivered.
etting and applications. Intracoronary infusion has been
he method of choice for nearly all studies in patients with
T-segment elevation MI. Other applications include stud-
es in chronic myocardial ischemia or ischemic LV dysfunc-
ion. Coronary transfer requires that target myocardium be
ubtended by an angiographically patent coronary artery or
dentifiable collateral vessel. The potential advantage of such
oronary cell transfer is the homogenous distribution of the
ells in the subtended target territory. Although distribution
s important, it might not translate to survival. It is known
hat bone marrow-derived stem cells survive when trans-
lanted into normal muscle or along the border zone of an
I, whereas myoblasts can be transplanted into an area
ith less blood flow, such as the scar area of an MI.
evices. Guide (5-F) and specialty catheters are preferred
or selective cell infusion, given the caliber of their internal
iameters. The technique typically uses commercially avail-
ble devices, such as over-the-wire (OTW) angioplasty
alloon catheters with short 8-mm balloons, to minimize
otential vascular trauma (Fig. 6). New devices are being
ested for the coronary perivascular (adventitial) delivery
ith the microneedle injection balloon catheter (Mercator,
an Leandro, California).
iming. The optimal time window for the coronary cell
ransfer seems to depend on the balance between multiple
utative and detrimental factors governing the infarction
ealing. This seems to be most favorable between days 3 and
after the infarction. The kinetics and timing of coronary
rterial cell delivery have received little attention in preclin-
cal studies, and transition from isolated small animals to
umans was rapid. Consequently, much of what is known
egarding cell retention after IC administration has been
earned from clinical studies. Clinical studies found a
ositive functional outcome if the cell injections were
erformed beyond day 3 (20). By contrast, efficacy of
oronary cell transfer at the later stages or in the chronic setting is still a matter of ongoing research and requires
etter understanding of humoral mediated homing.
ethodology. The basic set-up for IC delivery of biologics
s similar to balloon angioplasty with full heparinization
100 IU/kg) and hemodynamic and electrocardiographic
onitoring. The most commonly applied technique of
oronary cell transfer is anterograde delivery with selective
oronary injections. Cells are injected through the central
umen of the delivery catheter at slow or high flow rates
hile maintaining coronary flow (nonocclusive) or inter-
upting it with balloon occlusion (“stop-flow” method). In
oth cases, care is taken that the delivery catheter is flushed
ith heparinized saline before use to prevent intraluminal
lotting.
Currently, optimal timing for stem cell transplant is
nknown. There are multiple clinical trials underway to
nvestigate appropriate timing.
In the case of nonocclusive angioplasty method, a balloon
atheter or specialty catheters are used for the sub-selective
njection in the coronary vessel. The position of the catheter
s determined by the extent of the target territory. The
nternal lumen is at the proximal end connected to the
yringe containing the cell product. The cell product is
nfused as a continuous infusion or as a repetitive slow hand
njection. In the case of hand injection, the cell product is
oaded preferentially to the luer lock’s small volume syringe,
llowing smooth and controlled injections.
In the “stop-flow” method (Fig. 7), a balloon angioplasty
OTW) catheter is placed at the site of the stented segment
n the vicinity of the culprit lesion in the infarct-related
oronary artery. Care should be taken to avoid additional
njury to the stented segment. Accordingly, balloon length
hould be smaller than the nominal length of the stent. The
Figure 6. Intracoronary Delivery of Biologics
Images have been reprinted with permission of Springer Science and Busi-
ness Media (17). LAD  left anterior descending coronary artery; RCA 
right coronary artery; RCX  right circumﬂex artery.ize should be comparable or, at most, 0.5 mm larger than
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272he nominal size of the implanted stent. Likewise, low-
ressure balloon inflations are applied and typically do not
xceed the nominal inflation pressure. Before cell injection,
est inflation followed by test contrast can be performed to
ocument the coronary artery occlusion at the desired
egment. The cell product is loaded in the larger luer-lock
yringe (10 or 20 ml), connected via a 3-way stop-cock to a
mall volume luer-lock syringe (3 ml). The system is
onnected to the proximal internal lumen of the OTW
alloon catheter (Fig. 8). Cells are injected typically in
oluses of 3 ml. After balloon inflation, cells are slowly
njected over approximately 1-min, with a total occlusive
ime of 3 min. This timing is empirically chosen and is
ssociated with prolonged contact between the infused cell
roduct and the subtended endothelial surface of the macro-
nd microcirculation. After the 3-min occlusion period,
eperfusion is allowed for 2 to 3 min. The balloon occlusion
nd cell delivery cycle is repeated, followed by reperfusion,
ntil the process is complete. During balloon occlusion, the
Figure 7. Procedure of Percutaneous Intracoronary Transplantation of Bone
For intracoronary delivery of the cells, an over-the-wire angioplasty balloon ca
former infarct-related coronary occlusion where the stent had been implanted
the guidewire is removed, and the bone marrow-derived stem cells suspension
(C). Bone marrow-derived stem cells are infused with a pump at 1 to 2 ml/min
de-inﬂation and reperfusion until the total dose of cells is given to the patient
in the supplied myocardial area are checked after the procedure (D). Images hatient is monitored for signs of ischemia, arrhythmias, or wemodynamic instability. If severe arrhythmias, intolerable
schemia, or major hemodynamic instability are observed
uring balloon inflation, then the procedure should be
alted and injections modified according to the patient’s
olerance. If slow flow or signs of ischemia persist after
alloon deflation (or completion of injection via special
atheter), care should be taken to dilate the microvascula-
ure that might be partially obstructed by injected cells
especially if large cells or a high concentration of cells is
sed). Intracoronary administration of arteriolar vasodilator
nitroprusside, adenosine) should be considered. At the end
f the procedure, vessel patency and flow in the coronary
rtery are checked by control contrast injections. For IC cell
elivery at high flow rates after MI, cells are delivered in a
ingle 10-ml bolus over 30 s (20 ml/min) with a prototype
alloon catheter with a large inner lumen allowing delivery
t high flow rates. The catheter is placed in the mid LAD,
nd the balloon is inflated to a 1:1 ratio. A single infusion at
0 ml/min might be optimal from a safety standpoint
ow-Derived Stem Cells
oversized by 0.5 mm is used (A and B). After positioning at the site of the
alloon is inﬂated at low pressure (2 to 4 atms) to block blood ﬂow (B). Then,
fused through the internal lumen of the balloon under stop-ﬂow conditions
g periods of 3 min of inﬂation and cell infusion alternating with 1 min of
rity of the coronary artery used for transplantation and blood ﬂow perfusion
een reprinted with permission of Springer Science and Business Media (17).Marr
theter
, the b
is in
durin
. Integithout significantly decreasing cellular delivery (21).
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273raining requirements. Proctors should have experience in
C delivery of biologics (minimum of 10 cases) and be board
ertified in interventional cardiology or equivalent.
Trainees should observe at least 1 clinical case and
uccessfully perform 2 proctored cases and be board certified
n interventional cardiology (or equivalent).
oronary Sinus Delivery of Biologics
etting and applications. Percutaneous retrograde coronary
inus delivery is an alternative method for delivery of
ngiogenic proteins, genes, or stem cell therapy. The tech-
ique has been used for many years for delivery of cardiople-
ic solution in cardiovascular surgery and for protection
gainst myocardial ischemia in patients undergoing high-
isk percutaneous coronary interventions (22,23).
Retrograde coronary sinus delivery has been compared
ith both IC and IM delivery in preclinical models. Gene
herapy studies using retrograde coronary sinus delivery
emonstrated more homogenous delivery and increased
ene expression compared with IC delivery and IM delivery:
ither surgical epicardial approach or percutaneous endocar-
ial approach (24). Another study using retrograde coronary
inus delivery of fibroblast growth factor-2 demonstrated
mproved myocardial function and regional myocardial
lood flow compared with IC delivery. Coronary sinus
elivery resulted in a 2-fold increase in tissue binding of
broblast growth factor-2 (25).
The technique seems to be very safe and has potential
Figure 8. A 10-ml Luer Lock Syringe Connected Via 3-Way Stop-Cock to
3-ml Luer Lock Syringe
Images have been reprinted with permission of Springer Science and Busi-
ness Media (17).dvantages for more homogenous delivery across the myo-ardium. Theoretically, it might be lower risk than IM
elivery, with more uniform and higher rates of delivery.
he coronary sinus approach would also be available for
atients excluded from trials using percutaneous endomyo-
ardial delivery, such as patients with severe aortic valve
isease. Compared with IC delivery, it has the theoretical
dvantage of more homogeneous delivery, in particular, in
atients with severe subtotal stenosis (26).
ethodology. The technique involves placement of a cath-
ter into the coronary sinus via either the internal jugular or
emoral vein, with the infusion catheter placed over a wire.
single or double balloon is inflated, followed by infusion
f the angiogenic agent for 5 to 30 min at a pressure
pproximately 20 ml higher than the coronary sinus pres-
ure. The balloon inclusion time and infusion pressure
ight vary depending on the indication.
The TransAccess MicroLume Intramyocardial Injection
ystem (Medtronic, Inc., Santa Rosa, California) might be
n appropriate system to use for this delivery method. This
ystem can be used for angiogenesis, and myogenesis
hrough its venous approach with fluoroscopic guidance and
ccurate, stable targeting is achieved. It allows epicardial,
angential access to the myocardium, with a reduced risk of
mbolization.
raining requirements. Proctors should have experience in
C delivery of biologics (minimum of 10 cases) and be board
ertified in interventional cardiology or equivalent.
Trainees should observe at least 1 clinical case and
uccessfully perform 2 proctored cases and be board certified
n interventional cardiology (or equivalent).
Figure 9. Epicardial Delivery of Biologics by Direct Exposure and Injection
Images have been reprinted with permission of Springer Science and Busi-
ness Media (17).
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274picardial Delivery of Biologics
ettings and applications. Epicardial delivery for cell ther-
py is considered the most reliable method. Cells are
njected into the epicardium, which is highly accessible, due
o exposure by surgical incision (Fig. 9). Avoidance of
njection into epicardial arteries is achieved easily by direct
isualization. The concentration of the number of cell injec-
ions will depend on the dose intended for the patient (27).
The areas of injection are identified before surgery by
chocardiography and nuclear imaging and during surgery
y direct visualization. Transplanted cells are targeted to
schemic areas and/or scar tissue. Injections can be made
nto a beating or arrested heart and are made with either a
7-gauge customized pre-bent needle (for multiple perpen-
icular injections) or a straight needle, depending on the
echnique used.
The injection procedure can be performed by either of the
ollowing methods. For the first method, introduce the
eedle deep into the muscle in an oblique fashion. To verify
hat the needle is not inside the ventricle, apply suction to
he syringe, no aspiration of blood should occur, then inject
ntended dose. Next, pull the catheter back 0.5 to 1 cm and
nject the next intended dose. Repeat this process for the
pecific location. Use of this injection procedure will result
n fewer puncture sites. The second method is to select
eparate injection sites for each intended dose, thus increas-
ng the number of needle penetrations. The disadvantage of
his approach is that it increases the likelihood of leakage,
hereby decreasing the actual amount of injected material
hat can remain trapped in the myocardium. This issue can
e addressed by closing the puncture sites by finger pressure
r with a drop of surgical glue. The real efficacy of these
rocedures remains elusive.
It is currently unclear whether corticosteroids are needed
o reduce inflammatory responses possibly generated by the
njections. As such, IV corticosteroids might or might not
e given at the time of injection and 24 h after injection.
In the future, improvements could come from either
ore elaborate computer-driven injection devices (as used
or cell injections for patients with Parkinson’s disease) that
llow a tighter control over pressure, duration, and location
f injections or through the replacement of injection by
picardial application of cell-seeded biocompatible patches
r even scaffold-free cell sheets that are simply overlaid onto
he target area and maintained by glue or a couple of
titches.
raining requirements. Proctors should have experience in
C delivery of biologics (minimum of 5 cases) and be board
ertified in interventional cardiology (or equivalent).
Trainees should observe at least 1 clinical case and
uccessfully perform 2 proctored cases and be board certified
n interventional cardiology (or equivalent).All training recommendations are from the ISCTR to
rovide a framework for others who are interested in
ngaging in this new endeavor.
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